Skip to content Skip to footer
Disease of the Month: Epilepsy

Disease of the Month: Epilepsy

INTRODUCTIONAlso known as seizure disorder, epilepsy is a non-communicable chronic disorder of the brain and is the fourth most common neurological disease globally. It is a central nervous system (CNS) disorder characterized by recurrent episodes of seizures that are short changes in normal brain activity which led to brief incidences of involuntary movements either…

Read more

PharmaShots' Key Highlights of First Quarter 2022

PharmaShots’ Key Highlights of First Quarter 2022

The first quarter of 2022 highlights the approvals, clinical data & acquisitions. There are major alliances in this quarter which include Biocon acquired Viatris’ biosimilars assets for ~$3.335B, Stryker signed a definitive agreement to acquire Vocera Communications for ~$3.09B, Biohaven acquire Channel Biosciences for ~$3BThe first quarter of the year also showcases regulatory events…

Read more

Viewpoints_Bradley Galer

PharmaShots Interview: Zogenix’s Bradley Galer Shares Insight on Fintepla (fenfluramine, oral solution)

In an interview with PharmaShots, Bradley Galer, M.D., Chief Medical Officer at Zogenix shed light on data supporting the regulatory application and what the EU approval of Fintepla will mean in terms of reducing the high physical, emotional, and financial burden associated with the disease.Shots:Fintepla was approved by the EC in Dec'2020 as a new add-on therapy to…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]